SynthesisScientific reports2015
Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer.
Synthesis in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Association Between Immunosuppressive Therapy and Outcome of Clostridioides difficile Infection: Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2022Pooled it
- Radical prostatectomy versus deferred treatment for localised prostate cancer.The Cochrane database of systematic reviews · 2020Pooled it
- The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2020Pooled it
- The role of radical prostatectomy and definitive external beam radiotherapy in combined treatment for high-risk prostate cancer: a systematic review and meta-analysis.Asian journal of andrologyPooled it
- High-risk biochemical recurrence in prostate cancer: identification and early intervention strategies.Frontiers in urology · 2026Review
- Global Trends in Urological Evidence Synthesis: A Bibliometric Analysis of Systematic Reviews and Meta-analyses.Medical journal of the Islamic Republic of Iran · 2025Review
- Update on PSMA-based Prostate Cancer Imaging.Seminars in nuclear medicine · 2024Review
- A population-based propensity score matching analysis of risk factors and the impact on survival associated with refusal of cancer-directed surgery in patients with prostate cancer.Scientific reports · 2024Article
- Prostate-derived circulating microRNAs add prognostic value to prostate cancer risk calculators.Journal of extracellular biology · 2023Article
- Image-Guided Prostate Cryoablation: State-of-the-Art.Medicina (Kaunas, Lithuania) · 2023Review
- Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.Cell death & disease · 2023Article
- The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study.Journal of clinical medicine · 2022Article
- The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment.Seminars in nuclear medicine · 2022Review
- Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S).Scientific reports · 2022Article
- Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer.Cell proliferation · 2021Article
- Article
- Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer.Cell death & disease · 2021Article
- Magnetic Resonance-Guided Prostate Ablation.Seminars in interventional radiology · 2019Review
- A scoping review of patterns, motives, and risk and protective factors for adolescent firearm carriage.Journal of behavioral medicine · 2019Article
- Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT), androgen- deprivation therapy (ADT), and watchful waiting (WW) in high-risk prostate cancer (PCa). Overall, RP/(RT plus ADT) gave the best survival outcome in patients with high-risk PCa, whereas ADT/WW had the worst outcome. The overall priority for treatment strategy could be ranked as follows: RP/(RT plus ADT), RT, and ADT/WW. RP had significant better overall survival (OS) than RT or BT, and RP had significant lower cancer-specific mortality (CSM) than RT (0.51 [95% CI 0.30-0.73], P<0.001). ADT improved the cancer-specific survival (CSS) of RP based on a case-controlled study; added ADT to RT failed to challenge the position of RP but could improve the outcome of RT. In conclusions,RP/(RT plus adjuvant ADT) could both be used for the first-line therapy of high-risk PCa. When encountering an individual patient, urologists should consider various factors like tumors themselves, preferences of individuals, and so on.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.